TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Therapy With Varenicline and Bupropion for Smoking Cessation
Brief Summary: This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.


Options:
A: Arm Label: 1: Bup+MM; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Medication Management, Drug: placebo patch | Arm Label: 2 Bup+Mayo; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Mayo Counseling, Drug: placebo patch | Arm Label: 3 Patch+MM; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal system, Behavioral: Medication Management, Drug: placebo bupropion | Arm Label: 4 Patch+Mayo; Type: EXPERIMENTAL; Interventions: Drug: nicotine transdermal system, Behavioral: Mayo Counseling, Drug: placebo bupropion | Intervention Type: DRUG; Name: nicotine transdermal system; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: BEHAVIORAL; Name: Medication Management; Assigned to Arm(s): 1: Bup+MM, 3 Patch+MM | Intervention Type: BEHAVIORAL; Name: Mayo Counseling; Assigned to Arm(s): 2 Bup+Mayo, 4 Patch+Mayo | Intervention Type: DRUG; Name: placebo patch; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: DRUG; Name: placebo bupropion; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
C: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
D: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Therapy With Varenicline and Bupropion for Smoking Cessation
Brief Summary: This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.


Options:
A: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Varenicline | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Sugar pill
C: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Therapy With Varenicline and Bupropion for Smoking Cessation
Brief Summary: This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.


Options:
A: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
D: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Therapy With Varenicline and Bupropion for Smoking Cessation
Brief Summary: This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Therapy With Varenicline and Bupropion for Smoking Cessation
Brief Summary: This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.


Options:
A: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
C: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Eculizumab for the Treatment of Non-Exudative Age-Related Macular Degeneration: An Exploratory Study to Evaluate the Effects of C5 Inhibition on Drusen and Geographic Atrophy
Brief Summary: To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated by the change in drusen volume and area of geographic atrophy.


Options:
A: Arm Label: Lampalizumab once in every 4 weeks (Q4W); Type: EXPERIMENTAL; Interventions: Drug: Lampalizumab | Arm Label: Lampalizumab once in every 6 weeks (Q6W); Type: EXPERIMENTAL; Interventions: Drug: Lampalizumab | Arm Label: Sham Comparator; Type: SHAM_COMPARATOR; Interventions: Other: Sham Comparator | Intervention Type: DRUG; Name: Lampalizumab; Assigned to Arm(s): Lampalizumab once in every 4 weeks (Q4W), Lampalizumab once in every 6 weeks (Q6W) | Intervention Type: OTHER; Name: Sham Comparator; Assigned to Arm(s): Sham Comparator
B: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: oseltamivir + zanamivir | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir + zanamivir's placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir's placebo + zanamivir | Intervention Type: DRUG; Name: oseltamivir + zanamivir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oseltamivir + zanamivir's placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: oseltamivir's placebo + zanamivir; Assigned to Arm(s): 3
D: Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanical Ventilation With High Tidal Volume Induces Inflammation In Patients Without Lung Disease
Brief Summary: Objective: To compare the effects of a protective versus a conventional ventilatory strategy, on systemic and in lung production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-8 (IL-8) in patients without lung disease.

Hypothesis: High tidal volumes induce inflammation in patients without lung disease Design: Prospective control-randomized study. Patients and Setting: Twenty patients without lung disease and submitted to mechanical ventilation admitted to one trauma and one general adult intensive care unit of two different university hospitals.

Interventions: Patients were randomized to receive mechanical ventilation either with tidal volume (VT) of 10-12 ml/kg predicted body weight (high VT group) or with VT of 5-7 ml/kg predicted body weight (low VT group) with an O2 inspiratory fraction (FIO2) enough to keep arterial oxygen saturation \> 90% with positive end-expiratory pressure (PEEP) of 5 cmH2O during 12 hours after admission to the study.


Options:
A: Arm Label: high VT group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low tidal volume; Type: EXPERIMENTAL; Interventions: Procedure: Low tidal volume, Other: low tidal volume | Intervention Type: PROCEDURE; Name: Low tidal volume; Assigned to Arm(s): Low tidal volume | Intervention Type: PROCEDURE; Name: Low tidal volume; Assigned to Arm(s): Low tidal volume | Intervention Type: OTHER; Name: low tidal volume; Assigned to Arm(s): Low tidal volume
B: Arm Label: Individualized ventilation; Type: EXPERIMENTAL; Interventions: Procedure: Alveolar recruitment maneuver, Procedure: Calculation of optimal PEEP | Arm Label: Individualized vent. + postop. CPAP; Type: EXPERIMENTAL; Interventions: Procedure: Alveolar recruitment maneuver, Procedure: Calculation of optimal PEEP, Procedure: Postoperative CPAP | Arm Label: Standard ventilation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Standard vent. + postoperative CPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative CPAP | Intervention Type: PROCEDURE; Name: Alveolar recruitment maneuver; Assigned to Arm(s): Individualized vent. + postop. CPAP, Individualized ventilation | Intervention Type: PROCEDURE; Name: Calculation of optimal PEEP; Assigned to Arm(s): Individualized vent. + postop. CPAP, Individualized ventilation | Intervention Type: PROCEDURE; Name: Postoperative CPAP; Assigned to Arm(s): Individualized vent. + postop. CPAP, Standard vent. + postoperative CPAP
C: Intervention Type: OTHER; Name: Abdominal surgery; Assigned to Arm(s): N/A
D: Arm Label: conventional ventilation, protective ventilation; Type: OTHER; Interventions: Procedure: change ventilation | Intervention Type: PROCEDURE; Name: change ventilation; Assigned to Arm(s): conventional ventilation, protective ventilation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open Pilot Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly Followed Etanercept 25mg Twice Weekly, the Combination of Etanercept 25 mg Twice Weekly and Acitretin and Acitretin Alone in Patients With Moderate to Severe Psoriasis
Brief Summary: To compare the efficacy of ETN 50mg twice weekly for 12 weeks followed by reduction to a maintenance dose of 25mg twice weekly at week 24 with that of combination of ETN 25 mg Twice Weekly plus Acitretin 10mg BID at week 24 in subjects with moderate to severe psoriasis.


Options:
A: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)
B: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
C: Arm Label: 10 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 25 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 75 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 150 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Ixekizumab, Drug: Placebo | Arm Label: 120 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 80 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Intervention Type: BIOLOGICAL; Name: Ixekizumab; Assigned to Arm(s): 10 mg Ixekizumab, 120 mg Ixekizumab, 150 mg Ixekizumab, 25 mg Ixekizumab, 75 mg Ixekizumab, 80 mg Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open Pilot Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly Followed Etanercept 25mg Twice Weekly, the Combination of Etanercept 25 mg Twice Weekly and Acitretin and Acitretin Alone in Patients With Moderate to Severe Psoriasis
Brief Summary: To compare the efficacy of ETN 50mg twice weekly for 12 weeks followed by reduction to a maintenance dose of 25mg twice weekly at week 24 with that of combination of ETN 25 mg Twice Weekly plus Acitretin 10mg BID at week 24 in subjects with moderate to severe psoriasis.


Options:
A: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ixekizumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ixekizumab, Placebo
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
D: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Guselkumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Guselkumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Vitamin A Supplementation on Intestinal Parasitic Reinfections, Growth, Iron Status and Educational Achievement Among Orang Asli Schoolchildren in Pos Betau, Pahang, Malaysia
Brief Summary: Intestinal parasitic infections, malnutrition and iron deficiency anaemia (IDA) are still considered as public health problems in rural Malaysia especially among Orang Asli children. Despite intermittent control programmes, the prevalence of these problems is still high suggesting the need of other control and interventions measures. This randomized double-blind, placebo-controlled trial was carried out among Orang Asli schoolchildren from Sekolah Kebangsaan Betau in Pos Betau, Pahang (200 km northeast Kuala Lumpur) to investigate the effects of vitamin A supplementation on intestinal parasitic reinfections, growth, iron status and educational achievement.

HYPOTHESES

1. Vitamin A supplementation has a negative effect on intestinal parasitic reinfections and the worm burden of infections among Orang Asli schoolchildren in Pos Betau, Kuala Lipis, Pahang.
2. Vitamin A supplementation has a positive effect on growth (weight and height) among Orang Asli schoolchildren.
3. Vitamin A supplementation is effective in improving serum iron status among Orang Asli schoolchildren.
4. Vitamin A supplementation has a positive effect on cognitive function and educational achievement among Orang Asli schoolchildren.


Options:
A: Arm Label: Albendazole; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole
B: Arm Label: 1 dose, Albendazole , tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: albendazole | Arm Label: 2 doses, albendazole, tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: albendazole | Arm Label: 3 doses albendazole, 400mg, tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: albendazole | Intervention Type: DRUG; Name: albendazole; Assigned to Arm(s): 3 doses albendazole, 400mg, tablet | Intervention Type: DRUG; Name: albendazole; Assigned to Arm(s): 1 dose, Albendazole , tablet | Intervention Type: DRUG; Name: albendazole; Assigned to Arm(s): 2 doses, albendazole, tablet
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Single dose of mebendazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treatment with one of the two regimens of mebendazole | Arm Label: Multiple dose of mebendazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treatment with one of the two regimens of mebendazole | Intervention Type: DRUG; Name: Treatment with one of the two regimens of mebendazole; Assigned to Arm(s): Multiple dose of mebendazole, Single dose of mebendazole

Answer: C